Advertisment

FDA Clears BD MiniDraw: A Less-Invasive Finger-Prick Blood Collection System

author-image
Medriva Correspondents
New Update
NULL

FDA Clears BD MiniDraw: A Less-Invasive Finger-Prick Blood Collection System

Advertisment

Healthcare technology giant Becton Dickinson (BDX.N), widely recognized as BD, has announced a significant breakthrough in blood collection technology. The U.S. Food and Drug Administration (FDA) has bestowed its much-awaited clearance on BD's finger-prick blood collection device, the BD MiniDraw Collection System. This innovative device marks a shift towards less invasive options in the field of blood collection, eliminating the traditional need for venous blood draw.

Advertisment

BD MiniDraw Collection System: A Game-Changer

The BD MiniDraw Capillary Blood Collection System is engineered to facilitate the collection of blood samples for a broad range of commonly ordered lab tests. These include lipid panel tests and various tests for diagnosing and monitoring chronic conditions such as hypertension and high cholesterol. The system, offering a less invasive method for blood collection, can procure lab-quality blood samples from a mere fingerstick. This significant advancement has the potential to revolutionize diagnostic testing and expand health equity and access.

FDA 510(k) Clearance: A Mark of Trust

Advertisment

BD's MiniDraw Collection System has received 510(k) clearances from the FDA, confirming its safety and effectiveness. This clearance indicates that the device is as safe and effective as a legally marketed device that is not subject to premarket approval. The FDA's endorsement further fortifies the trust in this novel blood collection device, encouraging its adoption at a larger scale.

Advantages of the BD MiniDraw Collection System

Compared to traditional venous blood draw, the BD MiniDraw Capillary Blood Collection System is less invasive and more convenient. It paves the way for blood collection in unconventional locations, including retail pharmacies, thereby expanding access to essential diagnostic services. Not only does it make blood collection less daunting for patients, but it also facilitates low-volume blood collection for a lipid panel, select chemistry tests, and hemoglobin and hematocrit testing.

Advertisment

Future Plans: Expanding the Scope

BD has grand plans for the future of the MiniDraw Collection System. The company intends to expand the array of blood tests enabled by this device, further broadening its scope and usability. The system is part of a strategic partnership between BD and Babson Diagnostics, aimed at advancing the development of the Babson BetterWay blood testing ecosystem. This collaboration is expected to lead to significant advancements in blood testing technology.

Conclusion: A Leap Towards Better Health Access

The FDA's clearance of BD's MiniDraw Collection System is a significant development in the healthcare industry. This less-invasive blood collection device has the potential to transform diagnostic testing, making it more accessible, convenient, and patient-friendly. It brings us one step closer to achieving health equity and better access to diagnostic services, marking a crucial step in the journey towards healthcare innovation and advancement.

Advertisment
Chat with Dr. Medriva !